PharmaCorp to Acquire a Pharmacy in Ontario for $5,300,000, New Non-Binding Letter of Intent to Acquire Two Pharmacies in Eastern Canada, Updates on Previously Announced Non-Binding Letters of Intent and Filing of Q2 Investor Presentation

About this update from Pharmacorp Rx Inc.

[{"type":"text","content":"PharmaCorp to Acquire a Pharmacy in Ontario for $5,300,000, New Non-Binding Letter of Intent to Acquire Two Pharmacies in Eastern Canada, Updates on Previously Announced Non-Binding Letters of Intent and Filing of Q2 Investor Presentation\n\n\n\n SASKATOON, Saskatchewan, Sept. 08, 2025 (GLOBE NEWSWIRE) --\n \n PHARMACORP RX INC.\n \n (“\n \n PharmaCorp\n \n ” or the “\n \n Corporation\n \n ”) (TSXV: PCRX) is pleased to announce the signing of a definitive share purchase agreement to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business located in Ontario (the “\n \n Acquisition\n \n ”). This transaction marks PharmaCorp’s first acquisition under its charter company structure, which was established through the purchase completed on April 30, 2025. In addition, PharmaCorp has entered into a non-binding letter of intent to acquire two pharmacies in Atlantic Canada (the “\n \n Atlantic Canada LOI\n \n ”), is providing an update on the four transactions previously announced on May 29, 2025, and has filed its Q2 Investor Presentation.\n \n\n\n Acquisition\n \n\n\n PharmaCorp has entered into a definitive share purchase agreement, dated September 3, 2025 (the “\n \n Agreement\n \n ”), to acquire from arm’s length vendors (the “\n \n Vendors\n \n ”) a 100% interest in a PharmaChoice Canada bannered pharmacy business located in Eastern Canada. The purchase price for the Acquisition is $5,300,000, subject to customary adjustments (the “\n \n Purchase Price\n \n ”). The Purchase Price will be satisfied by cash on hand and available funds under the Corporation’s credit facility. Closing of the Acquisition is expected to occur on or about October 1, 2025, subject to satisfaction of customary closing conditions. No finder’s fees are payable in respect of the Acquisition.\n \n\n “This Acquisition represents an important milestone for PharmaCorp as our first PharmaChoice bannered transaction completed under the charter company structure we established earlier this year for Ontario,” said Al Simpson, Executive Chair of PharmaCorp. “Together with the announcement of one additional LOI, we continue to validate the strength of our platform, pipeline and acquisition model, anchored b...

More updates from Pharmacorp Rx Inc.